RxDoctor Payments Data

Carla Nickle, DO

Family Medicine · Greeneville, TNNPI 1508919911

Payments from drug & device makers

$7,460in general payments, 2019–2025

Across 501 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$794
  • Pfizer$655
  • Lilly USA, LLC$636
  • Otsuka America Pharmaceutical, Inc.$597
  • Boehringer Ingelheim$428
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,460 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$128,520
Medicare patients
231
Services billed
4,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$113,692
OzempicSemaglutide41$53,175
ProliaDenosumab21$36,477
Repatha SureclickEvolocumab43$29,925
ShingrixVaricella-Zoster Ge/As01b/Pf106$24,042
RexultiBrexpiprazole14$22,933
Nurtec OdtRimegepant Sulfate12$22,440
XareltoRivaroxaban27$21,141
TrulicityDulaglutide18$20,244
JardianceEmpagliflozin11$18,194
MounjaroTirzepatide16$16,424
Tresiba Flextouch U-100Insulin Degludec23$13,660
AbrysvoRsv Vacc, Pref A And Pref B/Pf36$11,809
Spiriva RespimatTiotropium Bromide16$10,305
Breo ElliptaFluticasone/Vilanterol21$8,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt, Abrysvo$655$147,941189 claims
Novo NordiskOzempic$794$53,17541 claims
GSKShingrix, Breo Ellipta, Arexvy$172$39,516150 claims
Lilly USA, LLCTrulicity, Mounjaro$636$36,66834 claims
AmgenProlia$148$36,47721 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$428$36,34244 claims
Otsuka America Pharmaceutical, Inc.Rexulti$597$22,93314 claims
Johnson & JohnsonXarelto$176$21,14127 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$283$7,53216 claims
AbbVieSynthroid$1,435$2,88142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Greeneville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →